VIM and hepatocellular carcinoma: Similarly, pinometostat, a DOT1L inhibitor currently in Phase I trials for MLL-rearranged leukemia [179], has shown potential in HCC by upregulating E-cadherin and downregulating Snai1 and VIM, thereby attenuating EMT and reducing invasiveness [180].